Propiverine

Summary

Propiverine (CHEMBL1078261) is an approved small molecule (ATC G04BD06); indicated across 3 conditions including overactive bladder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G04BD06
• Indications: 3 conditions
• Clinical trials: 13
• Chemistry: 367.5 Da · C23H29NO3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1078261
Name	Propiverine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	4942
ATC	G04BD06
Molecular formula	C23H29NO3
Molecular weight	367.5
InChIKey	QPCVHQBVMYCJOM-UHFFFAOYSA-N

SMILES: CCCOC(C1=CC=CC=C1)(C2=CC=CC=C2)C(=O)OC3CCN(CC3)C

IUPAC name: (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate

Also known as: Propiverina, Propiverine, SID50125813, PROPIVERINE, Propiverine Hydrochloride, propiverine

Parent form; salt/anhydrous children: CHEMBL2359059

Patent coverage: 1,236 distinct patent families (4,890 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 15 (assay-derived). Sample: 5-hydroxytryptamine receptor 2B, Voltage-dependent L-type calcium channel subunit alpha-1C, Muscarinic acetylcholine receptor M2, Muscarinic acetylcholine receptor M1, Motilin receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2C, Histamine H1 receptor, Mu-type opioid receptor, D(3) dopamine receptor, Voltage-dependent L-type calcium channel subunit alpha-1C, Kappa-type opioid receptor, Sodium-dependent dopamine transporter, Voltage-gated inwardly rectifying potassium channel KCNH2, Muscarinic acetylcholine receptor M3.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 17 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
CHRM1	6.23	AC50	590	nM	CHEMBL_ACT_25210777
OPRM1	6.12	AC50	750	nM	CHEMBL_ACT_25157560
CHRM3	6.08	AC50	830	nM	CHEMBL_ACT_25136848
CHRM1	5.77	AC50	1700	nM	CHEMBL_ACT_25135620
DRD3	5.6	AC50	2500	nM	CHEMBL_ACT_25193691
KCNH2	5.5	AC50	3200	nM	CHEMBL_ACT_25118096
OPRM1	5.44	AC50	3600	nM	CHEMBL_ACT_25147018
CHRM2	5.44	AC50	3600	nM	CHEMBL_ACT_25213892
HTR2C	5	AC50	9900	nM	CHEMBL_ACT_25131969

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
overactive bladder	3	MONDO:0006624	EFO:1000781

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 13.

Phase distribution

Phase	Trials
Not specified	7
PHASE3	3
PHASE4	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00903045	PHASE4	COMPLETED	Urinary Urgency Outcomes Following Propiverine Treatment for an Overactive Bladder
NCT02294396	PHASE4	COMPLETED	Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
NCT00646880	PHASE3	COMPLETED	A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring
NCT01512004	PHASE3	COMPLETED	Propiverine Hydrochloride Extended-Release Capsule for Overactive Bladder
NCT01530620	PHASE3	COMPLETED	Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity
NCT00795925	PHASE2	COMPLETED	Dose-Escalating Study of Propiverine Hydrochloride in Children Suffering From Overactive Bladder
NCT07028645	Not specified	ACTIVE_NOT_RECRUITING	Uroflowmetry and Nocturnal Enuresis
NCT07046156	Not specified	ACTIVE_NOT_RECRUITING	Treatment of Overactive Bladder With Anticholinergic Agents
NCT01942681	Not specified	COMPLETED	Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride
NCT02024945	Not specified	COMPLETED	Efficacy, Tolerability and Impact on Quality of Life of Propiverine in Patients With Overactive Bladder Syndrome
NCT03572231	Not specified	COMPLETED	A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
NCT03602508	Not specified	COMPLETED	Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
NCT03844581	Not specified	COMPLETED	Effect of Interferential Electrical Stimulation on Pain Perception and Disability Level on Interstitial Cystitis

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).